key: cord-0891282-e18mp8xe
authors: Alzahrani, Ali S.; Mukhtar, Noha; Aljomaiah, Abeer; Aljamei, Hadeel; Bakhsh, Abdulmohsen; Alsudani, Nada; Elsayed, Tarek; Alrashidi, Nahlah; Fadel, Roqayh; Alqahtani, Eman; Raef, Hussein; Butt, Muhammad Imran; Sulaiman, Othman
title: THE IMPACT OF COVID-19 VIRAL INFECTION ON THE HYPOTHALAMIC PITUITARY ADRENAL AXIS
date: 2020-12-28
journal: Endocr Pract
DOI: 10.1016/j.eprac.2020.10.014
sha: c1c77beea859bb88d84c8c02492d0f292cf00ef4
doc_id: 891282
cord_uid: e18mp8xe

CONTEXT: There are minimal data on the effects of COVID-19 on the endocrine organs. OBJECTIVE: To study the adrenocortical response to the acute COVID-19 infection METHODS: Morning plasma cortisol, ACTH and DHEAS were measured on day 1-2 of admission of 28 consecutive COVID-19 patients (16 males, 12 females, median age 45.5 years, range, 25-69). These tests were repeated twice in 20 patients and thrice in 15 patients on different days. The hormone levels were correlated with the severity of illness RESULTS: The median morning cortisol was 196 nmol/l (31-587). It was < 100 nmol/l in 8 patients (28.6%), < 200 nmol/l in 14 patients (50%) and < 300 nmol/l in 18 patients (64.3%). The corresponding ACTH values include a median of 18.5 ng/l (range 4-38), ACTH <10 ng/l in 7 patients (26.9%), < 20 ng/l in 17 patients (60.7%) and < 30 ng/l in 23 patients (82.1%). Repeated testing on different days showed a similar pattern. Overall, if a cutoff level of < 300 nmol/l is considered abnormal in the setting of acute illness, 9 patients (32%) had cortisol levels below this limit whether the test was done once only (3 patients) or three times (6 patients). The more severe the illness, the more patients with low cortisol and ACTH levels, suggesting a direct link between the COVID-19 infection and the impaired glucocorticoid response. CONCLUSIONS: Unexpectedly, the adrenocortical response in COVID-19 infection is impaired and a significant percentage of patients had plasma cortisol and ACTH consistent with central adrenal insufficiency.

An acute respiratory infection caused by a novel coronavirus (SARS-CoV-2) named officially as COVID-19 started in Wuhan, China in December 2019 and spread throughout the world (1). On 30 January 2020, the World Health Organization (WHO) officially declared the COVID-19 as a public health emergency of international concern (2). On 13 March 2020, the WHO declared COVID-19 as a global pandemic.

Worldwide, as of 5 October 2020, more than 35.5 million people have been infected and more than 1 million have died secondary to COVID-19 infection (https://www.worldometers.info/coronavirus/, accessed on 5 October 2020). The major impact of COVID-19 is on the respiratory system where the severity ranges from an asymptomatic patient detected on laboratory testing to flu-like symptoms to pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure and death (3) (4) (5) . The vast majority of patients have mild to moderate symptoms. However, about 10-15% have severe symptoms that need an intensive care unit and mechanical ventilation (3) (4) (5) .

Although the impact of COVID-19 is mainly on the respiratory system, many organs are affected, especially in patients with severe pneumonia and ARDS (3, 4, 6) . These include gastrointestinal tract, liver, kidneys, cardiovascular system, central nervous and musculoskeletal systems (6) (7) (8) (9) . Studies on the impact of COVID-19 on the endocrine organs are limited (6, 10) . The angiotensin converting enzyme 2 (ACE2) is the primary mechanism of entry of the virus and it is richly expressed in many endocrine glands (11). Therefore, the endocrine organs are likely to be involved, especially in patients with severe disease (6) . However, this has not been adequately assessed in COVID-19 infection. Adrenocortical function has been reported to be affected in acute illnesses (12, 13) 

Numerical values are expressed in median and range and categorical values in rates and percentages.

One-way ANOVA was used to compared cortisol levels between different COVID-19 severity of illness groups. The Statistical Package for the Social Sciences (SPSS) version 21 (IBM, Chicago) was used for the analysis.

J o u r n a l P r e -p r o o f Results:

A total of 28 patients were included in this study. Sixteen (57%) of these patients were completely healthy before contracting COVID-19 infection without any known medical illnesses. In contrast, the other 12 patients had medical conditions that are not known to interfere with adrenal function ( Table   1 ). The median age was 45.5 years (range 25-69) and the male: female ratio is 16:12. Eleven patients (39.3%) were in stage A, 15 (53.6%) in stage B and 2 (7.1%) in stage C. No patient was in stage D as we intentionally excluded patients admitted to the intensive care unit (ICU) to avoid the many confounding factors that may affect the adrenal function in the ICU setting. All patients had positive COVID-19 RT-PCR test. Computed Tomography (CT) scan was done in 6 patients and chest X-rays in all patients. A total of 7 patients had abnormal CT scan or chest X-rays; five patients had lung infiltrates on the chest CT scan and two out of 22 patients who did not have CT scan of the lungs had lung infiltrates on chest Xrays. The others had no evidence of lung infiltrates. All patients received azithromycin 500 mg daily for three days and hydroxychloroquine 400 mg loading dose followed by 200 mg BID for six days. Two patients received Tolicizumab, and four patients received ceftriaxone. All patients received oral and some received intravenous Acetaminophen for fever and pain but only two patients received opioids and this was on as needed basis and received only after the testing for this study was completed. Only one patient needed transfer to the Intensive Care Unit (ICU) after many days of admission and she died later. All patients were discharged home except one who died secondary to COVID-19 infection The median early morning cortisol level was 196 nmol/l (31-587). AM cortisol was < 100 nmol/l in 8 patients (28.6%), < 200 nmol/l in 14 patients (50%) and < 300 nmol/l in 18 patients (64.3%) ( Table 1,   Table 2 and Figure 1 ). The corresponding ACTH values include a median value of 18.5 ng/l (range 4-38), ACTH levels <10 ng/l in 7 patients (26.9%), < 20 ng/l in 17 patients (60.7%) and < 30 ng/l in 23 patients (82.1%) ( Table 2 ). All of these values were within or below the normal range of the assay (5-60 ng/dl).

Only one patient with a cortisol level of 429 nmol/l had a corresponding ACTH level above the normal range (357 ng/l).

We measured DHEAS in 24 cases. The median DHEAS level was 3.0 umol/l (range, 0.27-11), with the normal range for the assay of 1.81-8.3 umol/l. Four patients (16.7%) had DHEAS levels below and two patients (8.3%) above the normal range for the assay while all the other 18 patients (75%) had levels within the normal range.

Twenty patients (71.4%) had repeated tests on another day after the initial testing and 15 (53.6%) had repeated testing on three different days. The median plasma morning cortisol on the second time testing was 314.5 nmol/l . In this second time testing, AM cortisol level was < 100 nmol/l in 2 patients (10%), < 200 nmol/l in 6 patients (30%) and < 300 nmol/l in 9 patients (45%) (Table 2, Figure 2 ).

Of the 20 patients with repeated testing, 6 (30%) had further a drop while 14 (70%) had an increase in their cortisol level compared to the initial testing ( Figure 2 ). Using the cutoff limit of 300 nmol/l for diagnosis of possible adrenal insufficiency in this setting, 7 patients would qualify for such a diagnosis as their plasma AM cortisol remained below 300 nmol/l in the first and second testing ( Table 2 ). Two of these had cortisol level < 100 nmol/l, 5 less than 200 nmol/l and 7 < 300 nmol/l.

The corresponding median ACTH level was 27 ng/l (range 2-59). ACTH was below the normal range in only 2 patients (7.2%) and was in the normal range in the rest of 19 retested patients. None had an ACTH value above the upper limit of the normal range of 60 ng/l. Fifteen patients had repeated testing for the third time ( Figure 3 ). The median morning cortisol level was 238 nmol/l (57-594). Cortisol was <100 nmol/l in 3 patients (20%), < 200 nmol/l in 6 patients (40%) and < 300 nmol/l in 9 patients (60%) ( Table 2 ). The corresponding ACTH values include a median of 16.5 ng/l, < 10 ng/l in 5 cases, <20 ng/l in 8 cases and < 30 ng/l in 10 patients.

Overall, if morning plasma cortisol level below a cutoff level of 300 nmol/l is considered abnormal, 9

patients had cortisol levels below this limit whether the test was done once only (3 patients) or three times (6 patients) ( Figure 2 ).

Eleven cases (39.3%) had COVID-19 A severity score, 15 (53.6%) had B severity, and 2 (7.1%) had C severity score. The mean± SD plasma morning cortisol in these 3 groups were 259.9±183, 220.3±120, and 259.9±314.7 nmol/L, respectively (P 0.82). Of the 9 patients that were considered to have an inadequate cortisol response (<300 nmol/L), 2/11 in severity score A (18%), 6/15 (40%) were in severity score B, and 1/2 (50%) in severity score C ( (2-5, 8, 9) , the full spectrum of this new infectious illness is not fully realized. Although the main toll of illness involves the respiratory system, it has become clear that COVID-19 is a systemic illness that affects many organs in the body (3, 6, 17, 18) . However, limited data are available on these extra pulmonary manifestations and its pathophysiology (6, 19) . The data describing the effects of COVID-19 infection on the endocrine system are exceptionally scarce (6, 10, 19) . Driven by the well-known changes in the acute illness and its critical role in hemodynamic adaptation and hemostasis, we sought to study the response of the hypothalamic-pituitary-adrenal (HPA) axis in COVID-19 infection. We expected a robust response of the HPA axis with a significant rise in cortisol during the acute phase of COVID-19 infection. For our surprise, in none of the 28 patients included in this study such a brisk response in cortisol level was observed. By contrast, the cortisol level was mostly in the low side of the normal range or clearly low, frequently to levels that are diagnostic of adrenal insufficiency (Table 1 and Figure 1 ). Corresponding ACTH levels measured on the same samples were also on the lower side of normal range, suggesting that this is a form of secondary adrenal insufficiency. Whether this is due to a direct effect of the virus on the hypothalamus or pituitary glands or secondary to humoral response and release of inhibitory cytokines is not clear. DHEAS did not general floor and died secondary to COVID-19 infection. She was a 42-year old lady with no other morbidities. She came with severe respiratory symptoms (Grade C), and her morning serum cortisol was 482 nmol/l on day 1 of admission. Unfortunately, she did not have additional cortisol measurements.

Although there were no significant differences in the median cortisol levels between the three groups with different severities, there were more patients with "adrenal insufficiency" in more severe illness than in milder illness. Glucocorticoids are widely used in the management of acute illnesses, especially in the ICU setting (35) .

The concept of "relative adrenal insufficiency" or "critical illness-related corticosteroid insufficiency" in patients with acute stress and cortisol levels that are in the normal range but not matching the severity of illness continues to be a controversial issue (13, 35) . Although this term is widely entertained in the intensive care medicine, it is not as widely accepted in the endocrine community as it has little scientific evidence (36) . Studies suggested that cortisol level increases secondary to stress rather than to combat stress and is not necessary to survive stress (14, (36) (37) (38) . This does not negate the fact that some critically ill patients may benefit from glucocorticoids for their general supportive actions but not necessarily for adrenal insufficiency (14, 36) . It also does not contradict the fact that some patients may develop a real adrenal insufficiency for other reasons and need glucocorticoids. In COVID-19, the use of J o u r n a l P r e -p r o o f glucocorticoids was initially proposed as a general immunosuppressive measure to counteract the cytokine storm syndrome that was observed in severe COVID-19 infection (39, 40) . This was not based on evidence but rather on personal experiences and common sense recommendations derived from the known immunosuppressive effects of glucocorticoids (39, 40) . However, the recently announced RECOVERY trial documented a favorable outcome of patients treated with dexamethasone 6 mg daily for up to 10 days in addition to the usual care compared with patients treated with usual care alone(41).

In this trial, 2104 patients randomly received dexamethasone in addition to the usual care were M, male; F, female; DM 2, diabetes mellitus type 2; HTN, hypertension; IHD, ischemic heart disease J o u r n a l P r e -p r o o f 

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Coronavirus disease 2019 (COVID-19): situation report

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Organ-specific manifestations of COVID-19 infection

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing

Clinical progression of patients with COVID-19 in Shanghai

the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Endocrine responses to critical illness: novel insights and therapeutic implications

Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM)

CRITICALLY ILL PATIENTS: DISEASE STATE REVIEW

Corticosteroid insufficiency in acutely ill patients

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock

A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage

Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a 21. Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis

Association between high serum total cortisol concentrations and mortality from COVID-19

Molecular immune pathogenesis and diagnosis of COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy

Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2)

Multiple Functions of Angiotensin-Converting Enzyme 2 and Its Relevance in Cardiovascular Diseases

Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Bilateral Adrenal Hemorrhage in Coronavirus Disease

Patient: A Case Report

Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)

Molecular mimicry of ACTH in SARS -implications for corticosteroid treatment and prophylaxis

Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017

Relative adrenal insufficiency. Current Opinion in Endocrinology

Adaptation during surgical stress. A reevaluation of the role of glucocorticoids

Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients

Use of Corticosteroids in Coronavirus Disease